In a recent symposium at AACC in Atlanta entitled “The Convergence of Global Point-of-Care Diagnostic Needs,” some interesting ideas and experiences were presented by a diverse panel of experts. As diagnostic testing is moving closer to the patient in developing countries in order to facilitate treatment decisions during the clinical visit and new settings for POCT at decentralized locations such as retail pharmacies within the developed world are emerging, new opportunities and business models can be identified.
Interested in learning about the evolution of Point-of-Care molecular diagnostics? This article provides a very good overview of an area that is attracting both public and private funding and also points out the substantial growth anticipated for this market. Some of the key market drivers include:
Since 2011, Stratos has been engaged in a major global-health initiative to make Bill Gates' vision to quickly, easily, and affordably diagnose diseases a reality. This program is an unprecedented effort to develop affordable, easy-to-use tools that will enable health care workers in developing countries to precisely diagnose infectious disease at the point-of-care. These new tools are needed to enable each patient to receive the right therapy in a timely fashion.